India Startup Review

The Rise of Indian Biotech Startups: Insights from Anthem Biosciences

India Startup Review
22 Jul, 2025

India is rapidly emerging as a global hub for biotechnology, fueled by a robust scientific talent pool, cost-effective research and development capabilities, and increasing government support. This burgeoning sector is attracting significant investment, leading to the rise of innovative startups that are pushing the boundaries of pharmaceutical research and healthcare solutions. Among these pioneers, Anthem Biosciences stands out as a prominent Contract Research, Development, and Manufacturing Organization (CRDMO), playing a pivotal role in the drug discovery and development ecosystem.

Anthem Biosciences is not just a company; it's a testament to India's growing prowess in the life sciences. By offering comprehensive services from early-stage research to commercial manufacturing, Anthem enables global pharmaceutical and biotech companies to accelerate their drug pipelines. Its commitment to innovation and quality has positioned it as a critical partner in bringing new therapies and healthcare products to market, both domestically and internationally.

Market Position and Strategic Role

Anthem Biosciences operates at the heart of the biotech value chain, providing essential CRDMO services that span both chemistry and biology. This integrated approach allows the company to support clients across various stages of drug development, from target validation and medicinal chemistry to process development and manufacturing. This comprehensive service offering differentiates Anthem in a competitive landscape, making it a preferred partner for companies seeking end-to-end solutions.

The company's strategic importance is further highlighted by its recent activities, including a successful IPO in July 2025, which was fully subscribed, raising $395 million [1]. This strong investor confidence underscores the market's belief in Anthem's business model and its growth prospects. The IPO also saw significant participation from anchor investors, raising ₹1,016.02 crore, indicating institutional backing [2].

Anthem Biosciences has a strong global footprint, with significant revenues derived from North America, India, and other parts of Asia [3]. While a substantial portion of its revenues (75.3% in FY2023) comes from its top 10 customers, indicating a degree of customer concentration, its long-term associations and healthy share of business with these clients suggest stable relationships [4]. The company's valuation stands at approximately ₹7,450 crore, reflecting its significant position in the Indian biotech sector [5]

Financial Performance and Growth

Anthem Biosciences has demonstrated robust financial growth, solidifying its position as a key player in the Indian biotech sector. The company reported revenues of ₹1,845 crore in FY25, with a net profit of ₹451 crore for the same fiscal year [5]. This growth is indicative of the increasing demand for CRDMO services and Anthem’s ability to capture a significant share of the market. The company has consistently shown strong revenue growth, registering over 34% growth over Fiscal 2023 [6], and leading its peers with a 30% revenue growth in FY25 [7].

Anthem’s profitability is also noteworthy, with a healthy PAT (Profit After Tax) margin of 23% [7]. This strong financial health is a result of its efficient operations and high-value service offerings. The company’s focus on both chemistry and biology services has allowed it to diversify its revenue streams and maintain a competitive edge. Furthermore, Anthem Biosciences has successfully raised significant funding, with a total of $35.7 million over four funding rounds, including seed, early-stage, and grant rounds [5]. This funding has been instrumental in supporting its research and development initiatives and expanding its operational capabilities.

Impact on Indian Biotech and Future Outlook

Anthem Biosciences plays a crucial role in the growth and development of the Indian biotech industry. By providing comprehensive CRDMO services, it enables smaller biotech startups and larger pharmaceutical companies to bring their innovations to market more efficiently. This support is vital for fostering a vibrant and competitive biotech ecosystem in India. The company’s commitment to research and development, coupled with its state-of-the-art facilities, contributes significantly to India’s scientific advancements in the life sciences.

Looking ahead, Anthem Biosciences is well-positioned to capitalize on the continued growth of the global pharmaceutical and biotechnology markets. The increasing trend of outsourcing R&D and manufacturing to cost-effective and scientifically proficient regions like India bodes well for Anthem. The company’s recent IPO and strong financial performance provide it with the capital necessary for further expansion, technological upgrades, and potential strategic acquisitions. As India continues to strengthen its position as a global biotech hub, Anthem Biosciences is expected to remain at the forefront, driving innovation and contributing to the development of life-saving therapies and healthcare solutions.